

David C Rees

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8927095/publications.pdf>

Version: 2024-02-01

219
papers

10,751
citations

57681

46
h-index

42259

96
g-index

226
all docs

226
docs citations

226
times ranked

10621
citing authors

#	ARTICLE	IF	CITATIONS
1	Oxygen gradient ektacytometry does not predict pain in children with sickle cell anaemia. <i>British Journal of Haematology</i> , 2022, 197, 609-617.	1.2	9
2	Venous cerebral blood flow quantification and cognition in patients with sickle cell anemia. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2022, , 0271678X2110723.	2.4	8
3	Lung Clearance Index May Detect Early Peripheral Lung Disease in Sickle Cell Anemia. <i>Annals of the American Thoracic Society</i> , 2022, , .	1.5	3
4	A randomized, placebo-controlled, double-blind trial of canakinumab in children and young adults with sickle cell anemia. <i>Blood</i> , 2022, 139, 2642-2652.	0.6	17
5	What does the term "sickle cell disease"™ mean?. <i>British Journal of Haematology</i> , 2022, 197, 381-382.	1.2	1
6	Measurement of erythrocyte membrane mannoses to assess splenic function. <i>British Journal of Haematology</i> , 2022, , .	1.2	3
7	Automating Pitted Red Blood Cell Counts Using Deep Neural Network Analysis: A New Method for Measuring Splenic Function in Sickle Cell Anaemia. <i>Frontiers in Physiology</i> , 2022, 13, 859906.	1.3	8
8	Individual Watershed Areas in Sickle Cell Anemia: An Arterial Spin Labeling Study. <i>Frontiers in Physiology</i> , 2022, 13, 865391.	1.3	8
9	Update on the diagnosis and management of the autosomal dominant acute hepatic porphyrias. <i>Journal of Clinical Pathology</i> , 2022, 75, 537-543.	1.0	3
10	The erythrocyte membrane properties of beta thalassaemia heterozygotes and their consequences for <i>Plasmodium falciparum</i> invasion. <i>Scientific Reports</i> , 2022, 12, .	1.6	7
11	The use of next-generation sequencing in the diagnosis of rare inherited anaemias: A Joint BSH/EHA Good Practice Paper*. <i>British Journal of Haematology</i> , 2022, 198, 459-477.	1.2	3
12	Determinants of severity in sickle cell disease. <i>Blood Reviews</i> , 2022, 56, 100983.	2.8	13
13	Clinical management of sickle cell liver disease in children and young adults. <i>Archives of Disease in Childhood</i> , 2021, 106, 315-320.	1.0	10
14	Long-term oxygen therapy in children with sickle cell disease and hypoxaemia. <i>Archives of Disease in Childhood</i> , 2021, 106, 258-262.	1.0	3
15	Hydroxyurea: coming to conclusions on safety. <i>Blood</i> , 2021, 137, 728-729.	0.6	2
16	Pathophysiological Relevance of Renal Medullary Conditions on the Behaviour of Red Cells From Patients With Sickle Cell Anaemia. <i>Frontiers in Physiology</i> , 2021, 12, 653545.	1.3	1
17	Red blood cell mannoses as phagocytic ligands mediating both sickle cell anaemia and malaria resistance. <i>Nature Communications</i> , 2021, 12, 1792.	5.8	16
18	Hydroxyurea and blood transfusion therapy for Sickle cell disease in South Asia: inconsistent treatment of a neglected disease. <i>Orphanet Journal of Rare Diseases</i> , 2021, 16, 148.	1.2	7

#	ARTICLE	IF	CITATIONS
19	Oxidative status in the β^2 -thalassemia syndromes in Sri Lanka; a cross-sectional survey. <i>Free Radical Biology and Medicine</i> , 2021, 166, 337-347.	1.3	6
20	Improving the laboratory diagnosis of pyruvate kinase deficiency. <i>British Journal of Haematology</i> , 2021, 193, 994-1000.	1.2	4
21	The EHA Research Roadmap: Anemias. <i>HemaSphere</i> , 2021, 5, e607.	1.2	7
22	A Sri Lankan girl with a new genetic variant in the PKLR gene causing pyruvate kinase deficiency: a case report. <i>Journal of Medical Case Reports</i> , 2021, 15, 374.	0.4	0
23	What is the role of chest X-ray imaging in the acute management of children with sickle cell disease?. <i>British Journal of Haematology</i> , 2021, , .	1.2	1
24	Study of montelukast in children with sickle cell disease (SMILES): a study protocol for a randomised controlled trial. <i>Trials</i> , 2021, 22, 690.	0.7	2
25	A novel index to evaluate ineffective erythropoiesis in hematological diseases offers insights into sickle cell disease. <i>Haematologica</i> , 2021, , .	1.7	5
26	Pitfalls in the Diagnosis of β^2 -Thalassemia Intermedia. <i>Hemoglobin</i> , 2021, 45, 1-4.	0.4	0
27	Genome wide association study of silent cerebral infarction in sickle cell disease (HbSS and HbSC). <i>Haematologica</i> , 2021, 106, 1770-1773.	1.7	10
28	Sickle cell disease: More than a century of progress. Where do we stand now?. <i>Indian Journal of Medical Research</i> , 2021, 154, 4.	0.4	6
29	Initial Safety and Efficacy Results from the Phase II, Multicenter, Open-Label Solace-Kids Trial of Crizanlizumab in Adolescents with Sickle Cell Disease (SCD). <i>Blood</i> , 2021, 138, 12-12.	0.6	5
30	EXPLORE: A Prospective, Multinational, Natural History Study of Patients with Acute Hepatic Porphyria with Recurrent Attacks. <i>Hepatology</i> , 2020, 71, 1546-1558.	3.6	103
31	National comparative audit of blood transfusion: 2014 audit of transfusion services and practice in children and adults with sickle cell disease. <i>Transfusion Medicine</i> , 2020, 30, 186-195.	0.5	3
32	Higher oxygen saturation with hydroxyurea in paediatric sickle cell disease. <i>Archives of Disease in Childhood</i> , 2020, 105, 575-579.	1.0	8
33	Genetic Analysis of Patients With Sickle Cell Anemia and Stroke Before 4 Years of Age Suggest an Important Role for Apolipoprotein E. <i>Circulation Genomic and Precision Medicine</i> , 2020, 13, 531-540.	1.6	8
34	Beneficial effects of adenotonsillectomy in children with sickle cell disease. <i>ERJ Open Research</i> , 2020, 6, 00071-2020.	1.1	4
35	Comparison of pulse oximetry and earlobe blood gas with CO-oximetry in children with sickle cell disease: a retrospective review. <i>BMJ Paediatrics Open</i> , 2020, 4, e000690.	0.6	5
36	Phase 3 Trial of RNAi Therapeutic Givosiran for Acute Intermittent Porphyria. <i>New England Journal of Medicine</i> , 2020, 382, 2289-2301.	13.9	350

#	ARTICLE	IF	CITATIONS
37	Commentary on sickle cell non-invasive prenatal testing article. British Journal of Haematology, 2020, 190, 20-21.	1.2	1
38	Emerging therapies in sickle cell disease. British Journal of Haematology, 2020, 190, 149-172.	1.2	33
39	COVID-19 in patients with sickle cell disease - a case series from a UK Tertiary Hospital. Haematologica, 2020, 105, 2691-2693.	1.7	32
40	Sickle cell disease in Sri Lanka: clinical and molecular basis and the unanswered questions about disease severity. Orphanet Journal of Rare Diseases, 2020, 15, 177.	1.2	6
41	Laboratory diagnosis of G6PD deficiency. A British Society for Haematology Guideline. British Journal of Haematology, 2020, 189, 24-38.	1.2	29
42	Eighteen-Month Interim Analysis of Efficacy and Safety of Givosiran, an RNAi Therapeutic for Acute Hepatic Porphyria, in the Envision Open Label Extension. Blood, 2020, 136, 13-13.	0.6	4
43	Real-time national survey of COVID-19 in hemoglobinopathy and rare inherited anemia patients. Haematologica, 2020, 105, 2651-2654.	1.7	42
44	Study Design and Initial Baseline Characteristics in Solace-Kids: Crizanlizumab in Pediatric Patients with Sickle Cell Disease. Blood, 2020, 136, 22-24.	0.6	0
45	The Effect of Antioxidants on the Properties of Red Blood Cells From Patients With Sickle Cell Anemia. Frontiers in Physiology, 2019, 10, 976.	1.3	21
46	Genotype-phenotype association analysis identifies the role of β globin genes in modulating disease severity of β^E thalassaemia intermedia in Sri Lanka. Scientific Reports, 2019, 9, 10116.	1.6	10
47	The role of WNK in modulation of KCl cotransport activity in red cells from normal individuals and patients with sickle cell anaemia. Pflugers Archiv European Journal of Physiology, 2019, 471, 1539-1549.	1.3	4
48	The effects of hydroxycarbamide on the plasma proteome of children with sickle cell anaemia. British Journal of Haematology, 2019, 186, 879-886.	1.2	7
49	Index of Pain Experience in Sickle Cell Anaemia (<scp>IPESCA</scp>): development from daily pain diaries and initial findings from use with children and adults with sickle cell anaemia. British Journal of Haematology, 2019, 186, 360-363.	1.2	3
50	The effect of the antisickling compound GBT1118 on the permeability of red blood cells from patients with sickle cell anemia. Physiological Reports, 2019, 7, e14027.	0.7	7
51	Phase 1 Trial of an RNA Interference Therapy for Acute Intermittent Porphyria. New England Journal of Medicine, 2019, 380, 549-558.	13.9	194
52	End points for sickle cell disease clinical trials: patient-reported outcomes, pain, and the brain. Blood Advances, 2019, 3, 3982-4001.	2.5	51
53	Geographic Differences in Phenotype and Treatment of Children with Sickle Cell Anemia from the Multinational DOVE Study. Journal of Clinical Medicine, 2019, 8, 2009.	1.0	8
54	EHA Research Roadmap on Hemoglobinopathies and Thalassemia: An Update. HemaSphere, 2019, 3, e208.	1.2	13

#	ARTICLE	IF	CITATIONS
55	Addressing the diagnostic gaps in pyruvate kinase deficiency: Consensus recommendations on the diagnosis of pyruvate kinase deficiency. <i>American Journal of Hematology</i> , 2019, 94, 149-161.	2.0	55
56	A gain of function variant in PIEZO1 (E756del) and sickle cell disease. <i>Haematologica</i> , 2019, 104, e91-e93.	1.7	20
57	Double-Blind, Randomized Study of Canakinumab Treatment in Pediatric and Young Adult Patients with Sickle Cell Anemia. <i>Blood</i> , 2019, 134, 615-615.	0.6	3
58	The effect of xanthine oxidase and hypoxanthine on the permeability of red cells from patients with sickle cell anemia. <i>Physiological Reports</i> , 2018, 6, e13626.	0.7	2
59	How I manage red cell transfusions in patients with sickle cell disease. <i>British Journal of Haematology</i> , 2018, 180, 607-617.	1.2	23
60	Proteomic analysis of plasma from children with sickle cell anemia and silent cerebral infarction. <i>Haematologica</i> , 2018, 103, 1136-1142.	1.7	22
61	Heterogeneity of respiratory disease in children and young adults with sickle cell disease. <i>Thorax</i> , 2018, 73, 575-577.	2.7	12
62	High body mass index in children with sickle cell disease: a retrospective single-centre audit. <i>BMJ Paediatrics Open</i> , 2018, 2, e000302.	0.6	8
63	g(HbF): a genetic model of fetal hemoglobin in sickle cell disease. <i>Blood Advances</i> , 2018, 2, 235-239.	2.5	33
64	Oxidative stress and phosphatidylserine exposure in red cells from patients with sickle cell anaemia. <i>British Journal of Haematology</i> , 2018, 182, 567-578.	1.2	26
65	Lipid metabolism in terminal erythropoiesis. <i>Blood</i> , 2018, 131, 2872-2874.	0.6	4
66	Overnight auto-adjusting continuous airway pressure+standard care compared with standard care alone in the prevention of morbidity in sickle cell disease phase II (POMS2b): study protocol for a randomised controlled trial. <i>Trials</i> , 2018, 19, 55.	0.7	17
67	A survey of genetic fetal-haemoglobin modifiers in Nigerian patients with sickle cell anaemia. <i>PLoS ONE</i> , 2018, 13, e0197927.	1.1	18
68	An Audit of the Use of Gonadorelin Analogues to Prevent Recurrent Acute Symptoms in Patients with Acute Porphyria in the United Kingdom. <i>JIMD Reports</i> , 2017, 36, 99-107.	0.7	23
69	Sickle Cell Disease. <i>New England Journal of Medicine</i> , 2017, 376, 1561-1573.	13.9	898
70	Prasugrel hydrochloride for the treatment of sickle cell disease. <i>Expert Opinion on Investigational Drugs</i> , 2017, 26, 865-872.	1.9	8
71	Recommendations regarding splenectomy in hereditary hemolytic anemias. <i>Haematologica</i> , 2017, 102, 1304-1313.	1.7	138
72	Associations between environmental factors and hospital admissions for sickle cell disease. <i>Haematologica</i> , 2017, 102, 666-675.	1.7	29

#	ARTICLE	IF	CITATIONS
73	Update review of the acute porphyrias. <i>British Journal of Haematology</i> , 2017, 176, 527-538.	1.2	133
74	Newborn screening for haematological disorders. <i>Paediatrics and Child Health (United Kingdom)</i> , 2017, 27, 500-505.	0.2	0
75	Autoimmune Liver Disease in Children with Sickle Cell Disease. <i>Journal of Pediatrics</i> , 2017, 189, 79-85.e2.	0.9	25
76	The super sickling haemoglobin HbS α Oman: a study of red cell sickling, K ⁺ permeability and associations with disease severity in patients heterozygous for HbA and HbS α Oman (HbA/S α Oman) <i>Tj ETQq0 0 QrgBT /Overlock 10 T</i>		
77	Are the risks of treatment to cure a child with severe sickle cell disease too high?. <i>BMJ: British Medical Journal</i> , 2017, 359, j5250.	2.4	7
78	Early Markers of Sickle Nephropathy in Children With Sickle Cell Anemia Are Associated With Red Cell Cation Transport Activity. <i>HemaSphere</i> , 2017, 1, e2.	1.2	14
79	Real-time dose adjustment using point-of-care platelet reactivity testing in a double-blind study of prasugrel in children with sickle cell anaemia. <i>Thrombosis and Haemostasis</i> , 2017, 117, 580-588.	1.8	14
80	The significance of inadequate transcranial Doppler studies in children with sickle cell disease. <i>PLoS ONE</i> , 2017, 12, e0181681.	1.1	12
81	Design of the DOVE (Determining Effects of Platelet Inhibition on Vaso α Oclusive Events) trial: A global Phase 3 double α blind, randomized, placebo α controlled, multicenter study of the efficacy and safety of prasugrel in pediatric patients with sickle cell anemia utilizing a dose titration strategy. <i>Pediatric Blood and Cancer</i> , 2016, 63, 299-305.	0.8	13
82	Longitudinal assessment of lung function in children with sickle cell disease. <i>Pediatric Pulmonology</i> , 2016, 51, 717-723.	1.0	40
83	Nocturnal enuresis and K ⁺ transport in red blood cells from patients with sickle cell anemia. <i>Haematologica</i> , 2016, 101, e469-e472.	1.7	3
84	Haemoglobinopathies and the rheumatologist. <i>Rheumatology</i> , 2016, 55, 2109-2118.	0.9	17
85	Parents α ™ Experiences of Receiving the Initial Positive Newborn Screening (NBS) Result for Cystic Fibrosis and Sickle Cell Disease. <i>Journal of Genetic Counseling</i> , 2016, 25, 1215-1226.	0.9	40
86	How benign is sickle cell trait?. <i>EBioMedicine</i> , 2016, 11, 21-22.	2.7	20
87	Prasugrel for Sickle Cell Vaso-Occlusive Events. <i>New England Journal of Medicine</i> , 2016, 375, 185-186.	13.9	7
88	Extracranial internal carotid artery stenosis in children with sickle cell disease α “ Which transducer, what measurement?. <i>Ultrasound</i> , 2016, 24, 86-93.	0.3	0
89	Airway and alveolar nitric oxide production, lung function, and pulmonary blood flow in sickle cell disease. <i>Pediatric Research</i> , 2016, 79, 313-317.	1.1	11
90	A Multinational Trial of Prasugrel for Sickle Cell Vaso-Occlusive Events. <i>New England Journal of Medicine</i> , 2016, 374, 625-635.	13.9	117

#	ARTICLE	IF	CITATIONS
91	Lung function, transfusion, pulmonary capillary blood volume and sickle cell disease. <i>Respiratory Physiology and Neurobiology</i> , 2016, 222, 6-10.	0.7	21
92	Interim Data from a Randomized, Placebo Controlled, Phase 1 Study of Aln-AS1, an Investigational RNAi Therapeutic for the Treatment of Acute Hepatic Porphyria. <i>Blood</i> , 2016, 128, 2318-2318.	0.6	3
93	Sickle cell disease: Status with particular reference to India. <i>Indian Journal of Medical Research</i> , 2016, 143, 675.	0.4	8
94	The clinical significance of K-Cl cotransport activity in red cells of patients with HbSC disease. <i>Haematologica</i> , 2015, 100, 595-600.	1.7	18
95	Prevention of Morbidity in sickle cell disease - qualitative outcomes, pain and quality of life in a randomised cross-over pilot trial of overnight supplementary oxygen and auto-adjusting continuous positive airways pressure (POMS2a): study protocol for a randomised controlled trial. <i>Trials</i> , 2015, 16, 376.	0.7	10
96	Audit of the Use of Regular Haem Arginate Infusions in Patients with Acute Porphyria to Prevent Recurrent Symptoms. <i>JIMD Reports</i> , 2015, 22, 57-65.	0.7	65
97	13-valent pneumococcal conjugate vaccine (PCV13) is immunogenic and safe in children 6-17 years of age with sickle cell disease previously vaccinated with 23-valent pneumococcal polysaccharide vaccine (PPSV23): Results of a phase 3 study. <i>Pediatric Blood and Cancer</i> , 2015, 62, 1427-1436.	0.8	31
98	Novel mutations in PIEZO1 cause an autosomal recessive generalized lymphatic dysplasia with non-immune hydrops fetalis. <i>Nature Communications</i> , 2015, 6, 8085.	5.8	247
99	Environmental determinants of severity in sickle cell disease. <i>Haematologica</i> , 2015, 100, 1108-1116.	1.7	90
100	Prevention of Morbidity in Sickle Cell Disease (POMS 2): A Pilot Study of Nocturnal Respiratory Support Shows That Auto-Adjusting Positive Airways Pressure Is Safe and Is Preferred to Oxygen Therapy. <i>Blood</i> , 2015, 126, 993-993.	0.6	2
101	A Comprehensive Next Generation Sequencing Gene Panel Focused on Unexplained Anemia. <i>Blood</i> , 2015, 126, 946-946.	0.6	2
102	The haemoglobinopathies. , 2014, , 550-559.		0
103	Vitamin D deficiency and its correction in children with sickle cell anaemia. <i>Annals of Hematology</i> , 2014, 93, 2051-2056.	0.8	15
104	Cost-effectiveness analysis of preoperative transfusion in patients with sickle cell disease using evidence from the TAPS trial. <i>European Journal of Haematology</i> , 2014, 92, 249-255.	1.1	10
105	Urinary excretion of porphyrins, porphobilinogen and δ -aminolaevulinic acid following an attack of acute intermittent porphyria. <i>Journal of Clinical Pathology</i> , 2014, 67, 60-65.	1.0	50
106	Airways obstruction and pulmonary capillary blood volume in children with sickle cell disease. <i>Pediatric Pulmonology</i> , 2014, 49, 716-722.	1.0	38
107	Effects of 5-hydroxymethylfurfural on the volume and membrane permeability of red blood cells from patients with sickle cell disease. <i>Journal of Physiology</i> , 2014, 592, 4039-4049.	1.3	23
108	To begin at the beginning: sickle cell disease in Africa. <i>Lancet Haematology</i> , 2014, 1, e50-e51.	2.2	4

#	ARTICLE	IF	CITATIONS
109	Nontraumatic extradural hematoma in sickle cell anemia: A rare neurological complication not to be missed. <i>American Journal of Hematology</i> , 2014, 89, 225-227.	2.0	25
110	Managing the burden of sickle-cell disease in Africa. <i>Lancet Haematology</i> , 2014, 1, e11-e12.	2.2	3
111	Management of sickle cell disease in the community. <i>BMJ</i> , 2014, 348, g1765-g1765.	3.0	51
112	The spleen and sickle cell disease: the sick(led) spleen. <i>British Journal of Haematology</i> , 2014, 166, 165-176.	1.2	192
113	A Novel Alpha Spectrin Mutation Causing Severe Ineffective Erythropoiesis. <i>Blood</i> , 2014, 124, 4002-4002.	0.6	1
114	Direct and simultaneous quantitation of 5-aminolaevulinic acid and porphobilinogen in human serum or plasma by hydrophilic interaction liquid chromatography-atmospheric pressure chemical ionization/tandem mass spectrometry. <i>Biomedical Chromatography</i> , 2013, 27, 267-272.	0.8	14
115	Newborn screening for haematological disorders. <i>Paediatrics and Child Health (United Kingdom)</i> , 2013, 23, 472-479.	0.2	2
116	Combined blood transfusion and hydroxycarbamide in children with sickle cell anaemia. <i>British Journal of Haematology</i> , 2013, 160, 259-261.	1.2	19
117	The Transfusion Alternatives Preoperatively in Sickle Cell Disease (TAPS) study: a randomised, controlled, multicentre clinical trial. <i>Lancet</i> , 2013, 381, 930-938.	6.3	209
118	Best practice guidelines on clinical management of acute attacks of porphyria and their complications. <i>Annals of Clinical Biochemistry</i> , 2013, 50, 217-223.	0.8	96
119	A non-electrolyte haemolysis assay for diagnosis and prognosis of sickle cell disease. <i>Journal of Physiology</i> , 2013, 591, 1463-1474.	1.3	15
120	Morbidity pattern of sickle cell disease in India: a single centre perspective. <i>Indian Journal of Medical Research</i> , 2013, 138, 288-90.	0.4	5
121	Acute intermittent porphyria: fatal complications of treatment. <i>Clinical Medicine</i> , 2012, 12, 293-294.	0.8	25
122	The conductance of red blood cells from sickle cell patients: ion selectivity and inhibitors. <i>Journal of Physiology</i> , 2012, 590, 2095-2105.	1.3	30
123	Direct and simultaneous determination of 5-aminolaevulinic acid and porphobilinogen in urine by hydrophilic interaction liquid chromatography-electrospray ionisation/tandem mass spectrometry. <i>Biomedical Chromatography</i> , 2012, 26, 1033-1040.	0.8	11
124	Biomarkers in sickle cell disease. <i>British Journal of Haematology</i> , 2012, 156, 433-445.	1.2	100
125	Deoxygenation-induced and Ca ²⁺ dependent phosphatidylserine externalisation in red blood cells from normal individuals and sickle cell patients. <i>Cell Calcium</i> , 2012, 51, 51-56.	1.1	78
126	Changing Pattern of Hospital Admissions of Children With Sickle Cell Disease Over the Last 50 Years. <i>Journal of Pediatric Hematology/Oncology</i> , 2011, 33, 491-495.	0.3	10

#	ARTICLE	IF	CITATIONS
127	Soluble CD163 levels in children with sickle cell disease. <i>British Journal of Haematology</i> , 2011, 153, 105-110.	1.2	12
128	ENERCA clinical recommendations for disease management and prevention of complications of sickle cell disease in children. <i>American Journal of Hematology</i> , 2011, 86, 72-75.	2.0	33
129	The safety and efficacy of hydroxycarbamide in infants with sickle cell anemia. <i>Expert Review of Hematology</i> , 2011, 4, 407-409.	1.0	2
130	Portacaths are safe for long-term regular blood transfusion in children with sickle cell anaemia. <i>Archives of Disease in Childhood</i> , 2011, 96, 1082-1084.	1.0	20
131	The Properties of Red Blood Cells from Patients Heterozygous for HbS and HbC (HbSC Genotype). <i>Anemia</i> , 2011, 2011, 1-8.	0.5	25
132	Role of Calcium in Phosphatidylserine Externalisation in Red Blood Cells from Sickle Cell Patients. <i>Anemia</i> , 2011, 2011, 1-8.	0.5	25
133	The rationale for using hydroxycarbamide in the treatment of sickle cell disease. <i>Haematologica</i> , 2011, 96, 488-491.	1.7	36
134	Pre-Operative Transfusion Reduces Serious Adverse Events in Patients with Sickle Cell Disease (SCD): Results From the Transfusion Alternatives Preoperatively in Sickle Cell Disease (TAPS) Randomised Controlled Multicentre Clinical Trial. <i>Blood</i> , 2011, 118, 9-9.	0.6	23
135	Extracranial internal carotid arterial disease in children with sickle cell anemia. <i>Haematologica</i> , 2010, 95, 1287-1292.	1.7	48
136	Pandemic influenza A (H1N1) virus infections in children with sickle cell disease. <i>Blood</i> , 2010, 115, 2329-2330.	0.6	27
137	A retrospective analysis of outcome of pregnancy in patients with acute porphyria. <i>Journal of Inherited Metabolic Disease</i> , 2010, 33, 591-596.	1.7	28
138	Triose phosphate isomerase deficiency associated with two novel mutations in <i>TPI</i> gene. <i>European Journal of Haematology</i> , 2010, 85, 170-173.	1.1	10
139	Significant haemoglobinopathies: guidelines for screening and diagnosis. <i>British Journal of Haematology</i> , 2010, 149, 35-49.	1.2	230
140	Acute human parvovirus B19 infection and nephrotic syndrome in patients with sickle cell disease. <i>British Journal of Haematology</i> , 2010, 149, 289-291.	1.2	10
141	Outcome of adults with sickle cell disease admitted to critical care – experience of a single institution in the UK. <i>British Journal of Haematology</i> , 2010, 150, 610-613.	1.2	26
142	Outcome of children with sickle cell disease admitted to intensive care – a single institution experience. <i>British Journal of Haematology</i> , 2010, 150, 614-617.	1.2	12
143	Novel permeability characteristics of red blood cells from sickle cell patients heterozygous for HbS and HbC (HbSC genotype). <i>Blood Cells, Molecules, and Diseases</i> , 2010, 45, 46-52.	0.6	18
144	Sickle-cell disease. <i>Lancet</i> , The, 2010, 376, 2018-2031.	6.3	1,794

#	ARTICLE	IF	CITATIONS
145	Addition of Hydroxyurea to Transfusion Programme to Treat Progressive Cerebral Vasculopathy. <i>Blood</i> , 2010, 116, 4813-4813.	0.6	0
146	Orbital Compression Syndrome in Sickle Cell Crisis. <i>Klinische Padiatrie</i> , 2009, 221, 308-309.	0.2	4
147	The effects of air quality on haematological and clinical parameters in children with sickle cell anaemia. <i>Annals of Hematology</i> , 2009, 88, 529-533.	0.8	14
148	Stroke prevention in the young child with sickle cell anaemia. <i>Annals of Hematology</i> , 2009, 88, 943-946.	0.8	5
149	Hydroxycarbamide and erythropoietin in the preoperative management of children with sickle cell anaemia undergoing moderate risk surgery. <i>British Journal of Haematology</i> , 2009, 144, 453-454.	1.2	3
150	Neonatal screening for haematological disorders. <i>Paediatrics and Child Health (United Kingdom)</i> , 2009, 19, 372-376.	0.2	0
151	Auto-adjusting positive airway pressure in children with sickle cell anemia: results of a phase I randomized controlled trial. <i>Haematologica</i> , 2009, 94, 1006-1010.	1.7	57
152	Glucose 6 phosphate dehydrogenase deficiency is not associated with cerebrovascular disease in children with sickle cell anemia. <i>Blood</i> , 2009, 114, 742-743.	0.6	36
153	Extracranial Internal Carotid Arterial Disease in Children with Sickle Cell Disease.. <i>Blood</i> , 2009, 114, 2560-2560.	0.6	0
154	Hydroxyurea therapy lowers circulating DNA levels in sickle cell anemia. <i>American Journal of Hematology</i> , 2008, 83, 714-716.	2.0	18
155	The presence of β^0 -thalassaemia trait blunts the response to hydroxycarbamide in patients with sickle cell disease. <i>British Journal of Haematology</i> , 2008, 143, 589-592.	1.2	19
156	Transcranial Doppler scanning and the assessment of stroke risk in children with haemoglobin sickle cell disease. <i>Archives of Disease in Childhood</i> , 2008, 93, 138-141.	1.0	23
157	A Simple Index Using Age, Hemoglobin, and Aspartate Transaminase Predicts Increased Intracerebral Blood Velocity as Measured by Transcranial Doppler Scanning in Children With Sickle Cell Anemia. <i>Pediatrics</i> , 2008, 121, e1628-e1632.	1.0	35
158	Age-related changes in adaptation to severe anemia in childhood in developing countries. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2007, 104, 9440-9444.	3.3	54
159	Is routine molecular screening for common β^0 -thalassaemia deletions necessary as part of an antenatal screening programme?. <i>Journal of Medical Screening</i> , 2007, 14, 60-61.	1.1	9
160	Diagnosis and management of congenital haemolytic anaemia. <i>Clinical Medicine</i> , 2007, 7, 625-629.	0.8	5
161	Lung gas transfer in children with sickle cell anaemia. <i>Respiratory Physiology and Neurobiology</i> , 2007, 158, 70-74.	0.7	6
162	Free fetal DNA in maternal circulation: a potential prognostic marker for chromosomal abnormalities?. <i>Prenatal Diagnosis</i> , 2007, 27, 104-110.	1.1	26

#	ARTICLE	IF	CITATIONS
163	Temporal relationship of asthma to acute chest syndrome in sickle cell disease. <i>Pediatric Pulmonology</i> , 2007, 42, 103-106.	1.0	59
164	Airway hyperresponsiveness and acute chest syndrome in children with sickle cell anemia. <i>Pediatric Pulmonology</i> , 2007, 42, 272-276.	1.0	42
165	The associations between air quality and the number of hospital admissions for acute pain and sickle-cell disease in an urban environment. <i>British Journal of Haematology</i> , 2007, 136, 844-848.	1.2	35
166	Circulating DNA: a potential marker of sickle cell crisis. <i>British Journal of Haematology</i> , 2007, 139, 331-336.	1.2	19
167	Serum lactate dehydrogenase activity as a biomarker in children with sickle cell disease. <i>British Journal of Haematology</i> , 2007, 140, 071119224223004-???	1.2	33
168	Peak expiratory flow in Afro-Caribbean children with and without sickle cell anaemia. <i>Acta Paediatrica, International Journal of Paediatrics</i> , 2007, 96, 1308-1310.	0.7	1
169	Impact of acute chest syndrome on lung function of children with sickle cell disease. <i>Journal of Pediatrics</i> , 2006, 149, 17-22.	0.9	56
170	Trials in Sickle Cell Disease. <i>Pediatric Neurology</i> , 2006, 34, 450-458.	1.0	44
171	Haptoglobin-related protein is a high-affinity hemoglobin-binding plasma protein. <i>Blood</i> , 2006, 108, 2846-2849.	0.6	89
172	Cell-free DNA levels in pregnancies at risk of sickle-cell disease and significant ethnic variation. <i>British Journal of Haematology</i> , 2006, 135, 738-741.	1.2	15
173	Ethnicity Questions and Antenatal Screening for Sickle Cell/Thalassaemia [EQUANS] in England: A Randomised Controlled Trial of Two Questionnaires. <i>Ethnicity and Health</i> , 2006, 11, 169-189.	1.5	22
174	Rituximab in Children with Autoimmune Thrombocytopenia Complicating Underlying Congenital or Acquired Immunodeficiency State.. <i>Blood</i> , 2006, 108, 3977-3977.	0.6	1
175	The Impact of Local Air Quality on the Number of Hospital Admissions with Acute Pain in Sickle Cell Disease within an Urban Environment.. <i>Blood</i> , 2006, 108, 3790-3790.	0.6	0
176	Cell Free Fetal and Total DNA Levels in Pregnancies at Risk of Sickle Cell Disease and Significant Ethnic Variation.. <i>Blood</i> , 2006, 108, 3791-3791.	0.6	0
177	Desferrioxamine mesylate for managing transfusional iron overload in people with transfusion-dependent thalassaemia. , 2005, , CD004450.		18
178	The measurement of urinary hydroxyurea in sickle cell anaemia. <i>British Journal of Haematology</i> , 2005, 130, 138-144.	1.2	14
179	Stomatocytic haemolysis and macrothrombocytopenia (Mediterranean) Tj ETQq1 1 0.784314 rgBT /Overlock 10 Tf 50 107 Td (stomatocytosis) <i>British Journal of Haematology</i> , 2005, 130, 297-309.	1.2	138
180	Windy weather and low humidity are associated with an increased number of hospital admissions for acute pain and sickle cell disease in an urban environment with a maritime temperate climate. <i>British Journal of Haematology</i> , 2005, 131, 530-533.	1.2	61

#	ARTICLE	IF	CITATIONS
181	Exhaled carbon monoxide levels in children with sickle cell disease. <i>European Journal of Pediatrics</i> , 2005, 164, 162-165.	1.3	32
182	Introduction of Routine Screening for Cerebrovascular Abnormalities in Sickle Cell Disease (SCD) Using Transcranial Doppler Ultrasonography (TCD).. <i>Blood</i> , 2005, 106, 3786-3786.	0.6	0
183	Dehydrated hereditary stomatocytosis is associated with neonatal hepatitis. <i>British Journal of Haematology</i> , 2004, 126, 272-276.	1.2	10
184	Rituximab in chronic, recurrent HIV-associated immune thrombocytopenic purpura. <i>British Journal of Haematology</i> , 2004, 127, 607-608.	1.2	13
185	Diagnosis of plasma cell leukaemia: findings of the UK NEQAS for Leucocyte Immunophenotyping scheme. <i>International Journal of Laboratory Hematology</i> , 2004, 26, 37-42.	0.2	4
186	The Genetic Basis of the Interaction Between Pyrimidine 5â€™ Nucleotidase I Deficiency and Hemoglobin E. <i>Nucleosides, Nucleotides and Nucleic Acids</i> , 2004, 23, 1261-1263.	0.4	7
187	Epstein-Barr virusâ€‘related post-transplant lymphoproliferative disorder with t(9;14)(p11â€™¼12;q32). <i>Cancer Genetics and Cytogenetics</i> , 2003, 142, 134-136.	1.0	11
188	Pyrimidine 5â€™ Nucleotidase Deficiency. <i>British Journal of Haematology</i> , 2003, 120, 375-383.	1.2	56
189	Guidelines for the management of the acute painful crisis in sickle cell disease. <i>British Journal of Haematology</i> , 2003, 120, 744-752.	1.2	209
190	Heterocellular hereditary persistence of fetal haemoglobin affects the haematological parameters of Î²-thalassaemia trait. <i>British Journal of Haematology</i> , 2003, 123, 353-358.	1.2	15
191	Lamin B-receptor mutations in Pelger-HuÅ«t anomaly. <i>British Journal of Haematology</i> , 2003, 123, 542-544.	1.2	49
192	Molecular Analysis of the Î²-Globin Gene Cluster in the Niokholo Mandenka Population Reveals a Recent Origin of the Î²S Senegal Mutation. <i>American Journal of Human Genetics</i> , 2002, 70, 207-223.	2.6	115
193	Genetic basis of inosine triphosphate pyrophosphohydrolase deficiency. <i>Human Genetics</i> , 2002, 111, 360-367.	1.8	251
194	Factor V Leiden Mutation Screened by PCR and Detected with Lanthanide-Labeled Probes. <i>Genetic Testing and Molecular Biomarkers</i> , 2001, 5, 291-297.	1.7	5
195	A SECOND CASE OF Hb RENERT [Î²133(H11)Val â†’ Ala]. <i>Hemoglobin</i> , 2001, 25, 337-340.	0.4	3
196	Genetic basis of hemolytic anemia caused by pyrimidine 5â€™ nucleotidase deficiency. <i>Blood</i> , 2001, 97, 3327-3332.	0.6	59
197	Hemoglobin F and Hemoglobin E/Î²-Thalassemia. <i>The American Journal of Pediatric Hematology/Oncology</i> , 2000, 22, 567-572.	1.3	15
198	FLT3 internal tandem duplication mutations in adult acute myeloid leukaemia define a high-risk group. <i>British Journal of Haematology</i> , 2000, 111, 190-195.	1.2	257

#	ARTICLE	IF	CITATIONS
199	Are aberrant BCR-ABL transcripts more common than previously thought?. British Journal of Haematology, 2000, 111, 1109-1111.	1.2	31
200	Born to clot: the European burden. British Journal of Haematology, 1999, 105, 564-566.	1.2	100
201	Minisatellite mutational processes reduce F st estimates. Human Genetics, 1999, 105, 567-576.	1.8	15
202	Born to clot: the European burden. , 1999, 105, 564.		2
203	Reduced soluble transferrin receptor concentrations in acute malaria in Vanuatu.. American Journal of Tropical Medicine and Hygiene, 1999, 60, 875-878.	0.6	29
204	Elimination of Transfusions Through Induction of Fetal Hemoglobin Synthesis in Cooley's Anemiaa. Annals of the New York Academy of Sciences, 1998, 850, 100-109.	1.8	47
205	The Hemoglobin E Syndromes. Annals of the New York Academy of Sciences, 1998, 850, 334-343.	1.8	89
206	Nontransfusional Iron Overload in Thalassemia: Association with Hereditary Hemochromatosis. Annals of the New York Academy of Sciences, 1998, 850, 490-494.	1.8	22
207	Regression of extramedullary haemopoiesis and augmentation of fetal haemoglobin concentration during hydroxyurea therapy in β^2 thalassaemia. British Journal of Haematology, 1998, 101, 416-419.	1.2	74
208	Alpha thalassaemia is associated with increased soluble transferrin receptor levels. British Journal of Haematology, 1998, 103, 365-369.	1.2	72
209	Worldwide Distribution of a Common Methylenetetrahydrofolate Reductase Mutation. American Journal of Human Genetics, 1998, 62, 1258-1260.	2.6	230
210	Treatment of thalassaemia major with phenylbutyrate and hydroxyurea. Lancet, The, 1997, 350, 491-492.	6.3	63
211	Global distribution of the CCR5 gene 32-basepair deletion. Nature Genetics, 1997, 16, 100-103.	9.4	512
212	Influence of genetic predisposition to thrombosis on natural history of acute promyelocytic leukaemia. British Journal of Haematology, 1997, 96, 490-492.	1.2	15
213	Erythroblastic Inclusions in Dominantly Inherited β^2 Thalassemias. Blood, 1997, 89, 322-328.	0.6	45
214	Evidence for a single origin of factor V Leiden. British Journal of Haematology, 1996, 92, 1022-1025.	1.2	57
215	The Population Genetics of Factor V Leiden (Arg506Gln). British Journal of Haematology, 1996, 95, 579-586.	1.2	181
216	The metabolites of nitric oxide in sickle-cell disease. British Journal of Haematology, 1995, 91, 834-837.	1.2	69

